MRNIP and PKIA

Number of citations of the paper that reports this interaction (PubMedID 32296183)
86

Data Source:
BioGRID (two hybrid)

		MRNIP	PKIA
Description		MRN complex interacting protein	cAMP-dependent protein kinase inhibitor alpha
Image		No pdb structure
GO Annotations	Cellular Component	Nucleus Nucleoplasm	Nucleus Cytoplasm
	Molecular Function	Chromatin Binding Protein Binding	CAMP-dependent Protein Kinase Inhibitor Activity Protein Binding Protein Kinase A Catalytic Subunit Binding
	Biological Process	DNA Repair Cellular Response To DNA Damage Stimulus Mitotic G2 DNA Damage Checkpoint Signaling Response To Ionizing Radiation Positive Regulation Of Protein Kinase Activity Protein Localization To Chromatin Positive Regulation Of Double-strand Break Repair Via Homologous Recombination Regulation Of Double-strand Break Repair Via Nonhomologous End Joining	Negative Regulation Of Transcription By RNA Polymerase II Regulation Of G2/M Transition Of Mitotic Cell Cycle Negative Regulation Of Protein Import Into Nucleus Negative Regulation Of CAMP-dependent Protein Kinase Activity
Pathways
Drugs			3,5-Diiodotyrosine Hydroxyfasudil (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE H-89 5-(2-methylpiperazine-1-sulfonyl)isoquinoline N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE 3-pyridin-4-yl-1H-indazole 5-benzyl-1,3-thiazol-2-amine 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium Fasudil Myristic acid A-674563 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE Y-27632
Diseases
GWAS			Femoral neck bone mineral density ( 22504420) Intraocular pressure ( 29617998 31959993) Multiple sclerosis ( 21833088) Optic disc size ( 31809533) Systemic lupus erythematosus ( 28714469) Systolic blood pressure response to hydrochlorothiazide in hypertension ( 27802415)
Interacting Genes		9 interacting genes: DUSP23 EFHC1 EIF3E ENKD1 NUTF2 NXF1 PICK1 PKIA PSMB1	12 interacting genes: AGFG1 CASP6 DYNLL1 DYNLL2 EGFR JUNB MRNIP PRC1 PRKACA PRKACB PRKX XPO1
Entrez ID		51149	5569
HPRD ID		17420	05828
Ensembl ID		ENSG00000161010	ENSG00000171033
Uniprot IDs		Q6NTE8	A0A024R7Y9 P61925
PDB IDs			1CMK 1JLU 1Q8T 1VEB 1XH4 1XH5 1XH6 1XH7 1XH8 1XH9 1XHA 1YDR 2C1A 2C1B 2F7E 2GNI 2JDS 2JDT 2JDV 2L1L 2UVX 2UVY 2UVZ 2UW0 2UW3 2UW4 2UW5 2UW6 2UW7 2UW8 2VNW 2VNY 2VO0 2VO3 2VO6 2VO7 3AMA 3AMB 3L9L 3L9M 3L9N 3MVJ 3NX8 3OOG 3OVV 3OWP 3OXT 3P0M 3POO 3VQH 3WYG 3X2U 3X2V 3X2W 4AXA 4IAC 4IAD 4IAF 4IAI 4IAK 4IAY 4IAZ 4IB0 4IB1 4IB3 4IE9 4IJ9 4O21 4O22 4UJ1 4UJ2 4UJ9 4UJA 4UJB 4WB5 4WB6 4WB7 4WB8 4Z83 4Z84 5BX6 5BX7 5DH9 5LCP 5LCQ 5LCR 5LCT 5LCU 5M0B 5M0C 5M0L 5M0U 5M6V 5M6Y 5M71 5M75 5N23 5XOJ 6E21 6E99 6E9L 6FRX 6QJ7 6X2U 6X2V 6X2W
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?